The use of fixed-dose combination medicinal products (‘polypills’) for prevention and management of cardiovascular disease (CVD) has been of interest for many years.1,2 However, in contrast with fixed-dose combination products for HIV, tuberculosis and malaria, polypills for CVD have yet to become widely available and no such product is licensed for use in the UK. Two papers recently published in The Lancet have explored the evidence on the effectiveness of polypills and the challenges faced …